Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

This trial is comparing two neoadjuvant (pre-surgery) treatment combinations for locally advanced oral cavity squamous cell carcinoma (mouth cancer): standard chemotherapy (TPF — docetaxel, cisplatin, fluorouracil) versus a combination of an immunotherapy (anti-PD-1) plus two chemotherapy drugs (TP — cisplatin and paclitaxel). The goal is to shrink the tumor before surgery and improve the chances of complete removal. **You may be eligible if...** - You are 18–75 years old with a confirmed diagnosis of oral cavity squamous cell carcinoma (tongue, gums, cheek, floor of mouth, hard palate, or posterior molar area) - Your cancer is stage III or IVA (locally advanced but not yet spread to distant organs) - You have adequate blood counts, liver, kidney, and clotting function - Your general health allows chemotherapy and surgery (ECOG 0–2) **You may NOT be eligible if...** - You have already received treatment for this cancer - You have known allergy to study drugs - You have active autoimmune disease or are on chronic steroids - You have uncontrolled infections including HIV, Hepatitis B or C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.